Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT

Freigegeben

Zeitschriftenartikel

Clinical and molecular diagnosis of multiple endocrine neoplasia type 1

MPG-Autoren

Karges,  W
Max Planck Institute of Psychiatry, Max Planck Society;

Schaaf,  L
Max Planck Institute of Psychiatry, Max Planck Society;

Dralle,  H
Max Planck Institute of Psychiatry, Max Planck Society;

Boehm,  BO
Max Planck Institute of Psychiatry, Max Planck Society;

Externe Ressourcen
Es sind keine externen Ressourcen hinterlegt
Volltexte (beschränkter Zugriff)
Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.
Volltexte (frei zugänglich)
Es sind keine frei zugänglichen Volltexte in PuRe verfügbar
Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Karges, W., Schaaf, L., Dralle, H., & Boehm, B. (2002). Clinical and molecular diagnosis of multiple endocrine neoplasia type 1. Langenbecks Archives of Surgery, 386(8), 547-552.


Zitierlink: https://hdl.handle.net/11858/00-001M-0000-000E-A237-D
Zusammenfassung
Multiple endocrine neoplasia type 1 (MEN1) is a classic hereditary tumor syndrome characterized by a genetic predisposition to develop a variety of neuroendocrine neoplasias and hormone excess syndromes. The disease is caused by inactivating mutations of the MEN1 tumor suppressor gene, detectable in >95% of MEN1 families. The distinction of MEN1- associated tumors from sporadic neuroendocrine neoplasias is clinically important for providing optimal surgical and medical therapy, appropriate clinical follow-up, and counsel for affected patients and their families. Since MEN1 gene analysis became available in 1997, new diagnostic approaches have evolved in clinical management, to be reviewed in this article. Genetic screening of MEN1 families will allow definition of individual disease risk at a preclinical stage, thus helping to allocate medical resources and treatment as individually needed. These new diagnostic approaches are expected to reduce MEN1-associated morbidity and mortality, health care expenses, and psychological disease burde